You searched for MDD - Labiotech.eu

News and Trends 19 Aug 2022

Axsome Therapeutics’ MDD treatment gets green light from FDA

The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics, Inc.’s Auvelity tablets for the treatment of major depressive disorder (MDD) in adults. Auvelity (dextromethorphan HBr -bupropion HCl) is the first and only rapid-acting oral medicine approved for the treatment of MDD with labeling of statistically significant antidepressant efficacy compared to placebo starting at […]

August 19, 2022 - 4 minutesmins - By Jim Cornall

In Depth 13 Mar 2024

From LSD to healing minds: Where are we standing in psychedelic drug development?

Delve into the growing sector of psychedelic drug development to find out where we are coming from, and where we are standing in the field.

March 13, 2024 - 13 minutesmins - By Jules Adam

Best in Biotech 25 Jan 2024

Eight mental health biotech companies trying to make a difference to people’s lives

Take a closer look at eight mental health companies developing therapies that could make a different to people with mental illnesses.

January 25, 2024 - 11 minutesmins - By Willow Shah-Neville

Weekly Roundup 8 Dec 2023

Xenon’s $345 million public offering; EyePoint Pharmaceuticals’ trial success; gene therapy found to reduce liver cancer

What’s been going on in the world of biotech of late? Find out with Labiotech’s weekly roundup of the latest biotech news.

December 8, 2023 - 14 minutesmins - By Willow Shah-Neville

Weekly Roundup 10 Nov 2023

Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs

You are reading Labiotech’s weekly roundup of the latest biotech news. Korro Bio and Frequency Therapeutics close merger Last Friday, Korro Bio announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio. The combined company will now operate under the name Korro Bio, Inc. […]

November 10, 2023 - 12 minutesmins - By Willow Shah-Neville

Best in Biotech 3 Oct 2023

Five impactful biotech companies to know in New York

New York – the place where people of all backgrounds come with hopes and dreams of making a better life for themselves – is just recently becoming a life sciences powerhouse, attracting many biotech companies, after a $1 billion public investment in the industry from the City of New York. This initiative, called LifeSci NYC, […]

October 3, 2023 - 8 minutesmins - By Willow Shah-Neville

In Depth 23 May 2023

New antidepressants: tackling treatment resistant depression

Depression is thought to affect approximately 5% of adults worldwide. It encompasses several different depressive disorders, including major depressive disorder, seasonal affective disorder, and persistent depressive disorder, all of which can bring enormous difficulty to people’s lives, resulting in symptoms like poor concentration, hopelessness about the future, feeling tired or low in energy, and suicidal […]

May 23, 2023 - 8 minutesmins - By Willow Shah-Neville

Best in Biotech 20 Apr 2023

6 of the top biotech companies to know about in South San Francisco

South San Francisco is known as the birthplace of biotechnology, after Robert Swanson and Dr. Herbert Boyer founded biotech giant Genentech in 1976, eventually leading to other biotech companies and pharmaceutical companies basing themselves in the local area. In this article, we take a look at six biotech companies currently headquartered in South San Francisco. […]

April 20, 2023 - 7 minutesmins - By Willow Shah-Neville

Best in Biotech 3 Apr 2023

9 neuroscience biotech companies you should know about

Developing treatments for neurological diseases presents a huge challenge for neuroscience companies within the biotech industry. The central nervous system (CNS) is extremely complex and many neurological diseases can be difficult to treat due to the limited regenerative capacity of the CNS, and the fact that the blood-brain barrier – a specialized system of cells […]

April 3, 2023 - 10 minutesmins - By Willow Shah-Neville

News and Trends 18 Oct 2022

Empyrean Neuroscience launches with $22M to target CNS disorders

Empyrean Neuroscience, Inc. has launched with $22 million in series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous system (CNS). The company, based in New York City and Cambridge, U.K., is founded on a proprietary platform designed to genetically engineer small molecule therapeutics […]

October 18, 2022 - 2 minutesmins - By Jim Cornall

cancer cell screening drug discovery microplate

News and Trends 7 Oct 2022

GATC AI platform reduces time to find opioid use disorder candidates

GATC Health says the new drug candidates discovered by its proprietary AI drug discovery and prediction platform to treat opioid use disorder (OUD) and fentanyl addiction have entered pre-clinical development. GATC is partnering with Christie D. Fowler at the University of California, Irvine (UCI) and global scientific testing company, Eurofins Discovery, for the pre-clinical programs […]

October 7, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 23 Aug 2022

Gate Neurosciences emerges from stealth to tackle CNS diseases

Gate Neurosciences has officially launched to develop its next-generation therapeutics addressing synaptic dysfunction in patients suffering from central nervous system (CNS) disorders. Gate Neurosciences, a U.S. biotech company, was founded in 2019 by a team of neuroscience industry veterans to address the need for more effective treatments for CNS disorders, and to overcome long-standing challenges […]

August 23, 2022 - 3 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us